ASAdjaratou Fabienne Sanou

Adjaratou Fabienne Sanou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Adjaratou Fabienne Sanou has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 19 August 2023
      • Vol. 3  (3)
    Open Access

    [Prognostic factors and survival in adult acute leukemia in Burkina Faso].

    by Catherine Traoré, Koumpingnin Nebié, Salam Sawadogo, Adjaratou Fabienne Sanou, Arsène Héma, Éléonore Kafando

    Acute leukemia is both a diagnostic and therapeutic emergency. Our study aimed to describe the prognostic factors and survival of adults with acute leukemia in Burkina Faso. Cross-sectional descriptive study with retrospective data collection covering a period of 4.5 years (2018-2022) in two university hospitals in Burkina Faso. Were included all patients over 18 years hospitalized for acute leukemia in these sites with a usable medical record. A total of 42 cases were collected, of which 45% suffered from acute lymphoblastic leukemia and 43% from acute myeloid leukemia. In 12% of cases, acute leukemia was not classified. The average age was 35 ± 15 years, with extremes of 19 and 72 years. 12% of the patients presented an age of poor prognosis. Comorbidities were present in 14% of patients. The deterioration in general condition was fairly constant with 95% of patients at WHO stages 3 and 4. All patients presented with bone marrow failure syndrome and tumor syndrome was found in 45%. Anemia and thrombocytopenia were present in almost all cases. Hyperleukocytosis at diagnosis was present in 28 patients (67%); among them 18 patients (64%) had leukocytes greater than 50 G/L. Death in hospital was found in 38% of patients and loss of sight in 31%. The median survival was 3 months. Survival was 30% at 6 months and 0% at 12 months. Acute leukemias are in our practice conditions of poor prognosis with a fairly short survival.